Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Accumulated Expenses (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Accumulated Expenses for 16 consecutive years, with $17.7 million as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 21.63% year-over-year to $17.7 million; the TTM value through Dec 2025 reached $17.7 million, up 21.63%, while the annual FY2025 figure was $17.7 million, 21.63% up from the prior year.
  • Accumulated Expenses hit $17.7 million in Q4 2025 for Sangamo Therapeutics, up from $9.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $23.6 million in Q4 2023 and bottomed at $6.3 million in Q1 2024.
  • Average Accumulated Expenses over 5 years is $15.0 million, with a median of $14.4 million recorded in 2023.
  • Year-over-year, Accumulated Expenses surged 60.15% in 2021 and then tumbled 59.08% in 2024.
  • Sangamo Therapeutics' Accumulated Expenses stood at $20.8 million in 2021, then grew by 3.2% to $21.5 million in 2022, then rose by 9.52% to $23.6 million in 2023, then crashed by 38.15% to $14.6 million in 2024, then increased by 21.63% to $17.7 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $17.7 million, $9.9 million, and $15.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.